FLT3 and neoplasm: The subcutaneous tumor growth was significantly reduced (p < 0.05) upon i.p. αCD33-mAB-P/P-FLT3-siRNA application, but not upon control siRNA and PBS application, which again underlines the effective transport and activity of the nanocarrier (Fig. 4E).